1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese RNA Therapy Developers Extend Fundraising Streak Into December

 
• By Dexter Jie Yan

In the latest venture capital and private equity funding deals in China, SanegeneBio, Argo Biopharma and Ausper Biopharma raised a combined $136m on the back of their early-stage small interfering RNA and antisense oligonucleotide assets.

FUNDING word written on wood block
SanegeneBio financing one of biggest in RNA to date in 2023 • Source: Shutterstock

Chinese developers of RNA-based therapies, including small interfering RNA medicines, have extended their venture capital and private equity fundraising streak into early December.

Suzhou Sanegene Bio brought in one of the biggest rounds of financing in the RNA area so far in 2023. The Chinese RNA interference specialist on 1 December announced an...

More from China

More from Focus On Asia